Tanja Rixecker

573 total citations
5 papers, 427 citations indexed

About

Tanja Rixecker is a scholar working on Pathology and Forensic Medicine, Genetics and Neurology. According to data from OpenAlex, Tanja Rixecker has authored 5 papers receiving a total of 427 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pathology and Forensic Medicine, 3 papers in Genetics and 2 papers in Neurology. Recurrent topics in Tanja Rixecker's work include Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). Tanja Rixecker is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and CNS Lymphoma Diagnosis and Treatment (2 papers). Tanja Rixecker collaborates with scholars based in Germany and Switzerland. Tanja Rixecker's co-authors include Michael Pfreundschuh, Viola Poeschel, Carsten Zwick, Samira Zeynalova, Niels Murawski, Gerhard Held, Martin H. J. Wiesen, Marcel Reiser, Carsten Müller and Norbert Schmitz and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Tanja Rixecker

5 papers receiving 422 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tanja Rixecker Germany	5	316	234	151	91	53	5	427
Deborah Turner United Kingdom	7	456 1.4×	302 1.3×	167 1.1×	187 2.1×	42 0.8×	13	554
Joanna Gambell United Kingdom	6	436 1.4×	289 1.2×	157 1.0×	185 2.0×	42 0.8×	8	492
Pär Josefsson Denmark	10	252 0.8×	124 0.5×	179 1.2×	41 0.5×	38 0.7×	18	369
Isabella Capodanno Italy	10	374 1.2×	203 0.9×	137 0.9×	127 1.4×	117 2.2×	22	611
S.A.M. van de Schans Netherlands	14	209 0.7×	247 1.1×	68 0.5×	50 0.5×	16 0.3×	26	462
Zeena Salman United States	10	268 0.8×	158 0.7×	304 2.0×	23 0.3×	33 0.6×	27	576
Maya Hacini France	6	285 0.9×	189 0.8×	114 0.8×	81 0.9×	21 0.4×	15	358
Lenka Šmardová Czechia	9	256 0.8×	220 0.9×	42 0.3×	125 1.4×	24 0.5×	28	407
D F Moravec United States	6	466 1.5×	237 1.0×	143 0.9×	171 1.9×	51 1.0×	8	516
Dan Painter United Kingdom	6	251 0.8×	180 0.8×	129 0.9×	60 0.7×	19 0.4×	10	460

Countries citing papers authored by Tanja Rixecker

Since Specialization

Citations

This map shows the geographic impact of Tanja Rixecker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tanja Rixecker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tanja Rixecker more than expected).

Fields of papers citing papers by Tanja Rixecker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tanja Rixecker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tanja Rixecker. The network helps show where Tanja Rixecker may publish in the future.

Co-authorship network of co-authors of Tanja Rixecker

This figure shows the co-authorship network connecting the top 25 collaborators of Tanja Rixecker. A scholar is included among the top collaborators of Tanja Rixecker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tanja Rixecker. Tanja Rixecker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Pfreundschuh, Michael, Niels Murawski, Samira Zeynalova, et al.. (2017). Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients. British Journal of Haematology. 179(3). 410–420. 37 indexed citations

2.

Ziepert, Marita, Markus Kreuz, Ute Gödtel‐Armbrust, et al.. (2015). Association of NADPH Oxidase Polymorphisms with Anthracycline-Induced Cardiotoxicity in the RICOVER-60 Trial of Patients with Aggressive CD20 ⁺ B-Cell Lymphoma. Pharmacogenomics. 16(4). 361–372. 46 indexed citations

3.

Pfreundschuh, Michael, Viola Poeschel, Samira Zeynalova, et al.. (2014). Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. Journal of Clinical Oncology. 32(36). 4127–4133. 59 indexed citations

4.

Pfreundschuh, Michael, Carsten Müller, Samira Zeynalova, et al.. (2013). Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 123(5). 640–646. 99 indexed citations

5.

Müller, Carsten, Niels Murawski, Martin H. J. Wiesen, et al.. (2012). The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 119(14). 3276–3284. 186 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact